These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11224652)

  • 1. Hyperlipidemia and inhibitors of HIV protease.
    Distler O; Cooper DA; Deckelbaum RJ; Sturley SL
    Curr Opin Clin Nutr Metab Care; 2001 Mar; 4(2):99-103. PubMed ID: 11224652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
    Graham NM
    J Acquir Immune Defic Syndr; 2000 Oct; 25 Suppl 1():S4-11. PubMed ID: 11126425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
    Schwenk A
    Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
    [No Abstract]   [Full Text] [Related]  

  • 5. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection.
    Graber AL
    Endocr Pract; 2001; 7(6):430-7. PubMed ID: 11747278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
    Yanovski JA; Miller KD; Kino T; Friedman TC; Chrousos GP; Tsigos C; Falloon J
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1925-31. PubMed ID: 10372688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood lipid abnormalities during treatment with protease inhibitors].
    Vergès B; Petit JM
    Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fat, sugar and drugs on the French Riviera.
    Lands L
    GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.
    Domingo P; Matias-Guiu X; Pujol RM; Francia E; Lagarda E; Sambeat MA; Vázquez G
    AIDS; 1999 Nov; 13(16):2261-7. PubMed ID: 10563711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 12. [The lipodystrophy syndrome and protease inhibitor therapy in HIV infection].
    Djokic M; Bojic I; Mikic D; Begovic V; Kuljic-Kapulica N; Karadaglic Dj; Dimitrijevic-Rajic R; Curcic P; Hristovic D
    Vojnosanit Pregl; 2001; 58(4):433-5. PubMed ID: 11712226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome--is there a link?
    Wilson JD; Dunham RJ; Balen AH
    Sex Transm Infect; 1999 Aug; 75(4):268-9. PubMed ID: 10615316
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.
    van der Valk M; Bisschop PH; Romijn JA; Ackermans MT; Lange JM; Endert E; Reiss P; Sauerwein HP
    AIDS; 2001 Nov; 15(16):2093-100. PubMed ID: 11684928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in body shape and metabolic abnormalities.
    Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fat city: understanding HIV lipodystrophy.
    Flexner C
    Hopkins HIV Rep; 1998 Sep; 10(5):14-5. PubMed ID: 11365774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
    Carr A; Samaras K; Chisholm DJ; Cooper DA
    Lancet; 1998 Jun; 351(9119):1881-3. PubMed ID: 9652687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic complications associated with use of protease inhibitors].
    Mosnier-Pudar H
    Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV protease inhibitor-related lipodystrophy syndrome.
    Carr A
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S135-42. PubMed ID: 10860898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.